Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals (APLS)
:APLS
APLS Analyst Ratings
Moderate Buy
10 Buy
8 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
APLS Stock 12 Month Forecast
Average Price Target
$35.65
▲(104.53%Upside)
| Highest Price Target$60.00 | Average Price Target$35.65 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$17.5
Hold
0.40%
Upside
Reiterated
06/28/25
The overall stock score for Apellis Pharmaceuticals is driven primarily by its financial performance challenges, reflected in persistent net losses and negative cash flows. Technical analysis indicates weak market momentum, while valuation metrics suggest the stock may be overvalued. Despite some positive developments in the earnings call, such as FDA Priority Review for EMPAVELI, the revenue shortfalls and operational challenges weigh heavily on the score.
Bank of America Securities
$23
Hold
31.96%
Upside
Reiterated
06/12/25
William Blair
―
Buy
―
Reiterated
06/09/25
Stifel Nicolaus
$60
Buy
244.23%
Upside
Reiterated
06/06/25
Wells Fargo
$26→$29
Hold
66.38%
Upside
Reiterated
06/02/25
Piper Sandler
$26
Hold
49.17%
Upside
Reiterated
05/28/25
Citi
$49→$41
Buy
135.23%
Upside
Reiterated
05/22/25
J.P. Morgan
$45→$35
Buy
100.80%
Upside
Reiterated
05/22/25
Mizuho Securities
$30→$20
Hold
14.74%
Upside
Reiterated
05/14/25
Cantor Fitzgerald
$75→$52
Buy
198.34%
Upside
Reiterated
05/09/25
Raymond James
$52
Buy
198.34%
Upside
Downgraded
05/09/25
H.C. Wainwright
$57
Buy
227.02%
Upside
Reiterated
05/08/25
Scotiabank
$31→$20
Hold
14.74%
Upside
Reiterated
05/08/25
Morgan Stanley
$30→$25
Hold
43.43%
Upside
Reiterated
05/08/25
Robert W. Baird
$55→$47
Buy
169.65%
Upside
Reiterated
05/08/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$17.5
Hold
0.40%
Upside
Reiterated
06/28/25
The overall stock score for Apellis Pharmaceuticals is driven primarily by its financial performance challenges, reflected in persistent net losses and negative cash flows. Technical analysis indicates weak market momentum, while valuation metrics suggest the stock may be overvalued. Despite some positive developments in the earnings call, such as FDA Priority Review for EMPAVELI, the revenue shortfalls and operational challenges weigh heavily on the score.
Bank of America Securities
$23
Hold
31.96%
Upside
Reiterated
06/12/25
William Blair
―
Buy
―
Reiterated
06/09/25
Stifel Nicolaus
$60
Buy
244.23%
Upside
Reiterated
06/06/25
Wells Fargo
$26→$29
Hold
66.38%
Upside
Reiterated
06/02/25
Piper Sandler
$26
Hold
49.17%
Upside
Reiterated
05/28/25
Citi
$49→$41
Buy
135.23%
Upside
Reiterated
05/22/25
J.P. Morgan
$45→$35
Buy
100.80%
Upside
Reiterated
05/22/25
Mizuho Securities
$30→$20
Hold
14.74%
Upside
Reiterated
05/14/25
Cantor Fitzgerald
$75→$52
Buy
198.34%
Upside
Reiterated
05/09/25
Raymond James
$52
Buy
198.34%
Upside
Downgraded
05/09/25
H.C. Wainwright
$57
Buy
227.02%
Upside
Reiterated
05/08/25
Scotiabank
$31→$20
Hold
14.74%
Upside
Reiterated
05/08/25
Morgan Stanley
$30→$25
Hold
43.43%
Upside
Reiterated
05/08/25
Robert W. Baird
$55→$47
Buy
169.65%
Upside
Reiterated
05/08/25
Best Analysts Covering Apellis Pharmaceuticals
1 Month
xxx
Success Rate
18/28 ratings generated profit
Average Return
+4.13%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +4.13% per trade.
3 Months
xxx
Success Rate
17/27 ratings generated profit
Average Return
+3.33%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.96% of your transactions generating a profit, with an average return of +3.33% per trade.
1 Year
Success Rate
13/29 ratings generated profit
Average Return
+0.55%
reiterated a buy rating last month
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 44.83% of your transactions generating a profit, with an average return of +0.55% per trade.
2 Years
xxx
Success Rate
14/27 ratings generated profit
Average Return
-2.54%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 51.85% of your transactions generating a profit, with an average return of -2.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
APLS Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
13
20
18
17
11
Buy
4
5
5
6
5
Hold
18
23
22
23
19
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
48
45
46
35
Each month's total comprises the sum of three months' worth of ratings.
APLS Financial Forecast
APLS Stock Forecast FAQ
What is APLS’s average 12-month price target, according to analysts?
Based on analyst ratings, Apellis Pharmaceuticals’s 12-month average price target is 35.65.
What is APLS’s upside potential, based on the analysts’ average price target?
Apellis Pharmaceuticals has 104.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is APLS a Buy, Sell or Hold?
Apellis Pharmaceuticals has a consensus rating of Moderate Buy which is based on 10 buy ratings, 8 hold ratings and 0 sell ratings.
What is Apellis Pharmaceuticals’s price target?
The average price target for Apellis Pharmaceuticals is 35.65. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $18.00. The average price target represents 104.53% Increase from the current price of $17.43.
The highest analyst price target is $60.00 ,the lowest forecast is $18.00. The average price target represents 104.53% Increase from the current price of $17.43.
What do analysts say about Apellis Pharmaceuticals?
Apellis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of APLS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.